{"id":48284,"date":"2023-08-14T15:13:09","date_gmt":"2023-08-14T19:13:09","guid":{"rendered":"https:\/\/ifintechworld.com\/markets\/is-amgen-stock-fully-valued-after-a-17-rise-in-a-month\/"},"modified":"2023-08-14T15:13:11","modified_gmt":"2023-08-14T19:13:11","slug":"is-amgen-stock-fully-valued-after-a-17-rise-in-a-month","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=48284","title":{"rendered":"Is Amgen Stock Fully Valued After A 17% Rise In A Month?"},"content":{"rendered":"<div>\n<p><strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/AMGN\/\">Amgen stock<\/strong> (NASDAQ<fbs-ticker data-name=\"NDAQ\" data-href=\"https:\/\/www.forbes.com\/companies\/nasdaq\" data-type=\"stock\"><br \/>\n  NDAQ<br \/>\n <\/fbs-ticker>: AMGN) has seen a 17% rise in a month, outperforming the broader S&amp;P500 index, up 1%. The recent rise can be attributed to its upbeat Q2 results. The company reported revenues of $7.0 billion, up 6% y-o-y, faring better than the consensus estimate of $6.7 billion. Also, its bottom line of $5.00 on a per share and adjusted basis was comfortably above the $4.46 consensus estimate. Adjusted operating margin contracted about 50 bps to 52.6% in the quarter, partly due to higher R&amp;D costs.<\/p>\n<p>Interestingly, AMGN stock had a Sharpe Ratio of <strong>0.4<\/strong> since early 2017, which is lower than <strong>0.6<\/strong> for the S&amp;P 500 Index over the same period. This compares with the <strong>Sharpe of 1.2<\/strong> for the Trefis Reinforced Value portfolio. Sharpe is a measure of return per unit of risk, and high-performance portfolios can provide the best of both worlds.<\/p>\n<p>If we look at the longer term, AMGN stock is up 16% from levels seen in late 2021, faring better than the S&amp;P 500 index, down around 6%. This 16% rise for Amgen<fbs-ticker data-name=\"AMGN\" data-href=\"https:\/\/www.forbes.com\/companies\/amgen\" data-type=\"stock\"><br \/>\n  AMGN<br \/>\n <\/fbs-ticker> stock since late 2021 can be attributed to <strong>1.<\/strong> the company\u2019s P\/S ratio expanding 10% to 5.3x revenues vs. 4.8x in 2021, <strong>2. <\/strong>a 3.4% fall in its total shares outstanding to 535 million, and <strong>3.<\/strong> <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/AMGN\/no-login-required\/qNXDIdG6\/Amgen-Revenue?fromforbesandarticle=trefis230814\">Amgen\u2019s revenue<\/strong><strong> <\/strong>growth of 2,3% to $27 billion over the last twelve months, compared to $26 billion in 2021. This has meant that the company\u2019s revenue per share metric has risen 6% to $49.70 now, compared to $46.90 in 2021\u2014our dashboard on <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/AMGN\/no-login-required\/2rXavUZh\/Why-Amgen-Stock-Moved-AMGN-Stock-Has-Gained-16-Since-2021-Primarily-Due-To-Favorable-Change-In-Price-To-Sales-Multiple-P-S-?fromforbesandarticle=trefis230814\">Why Amgen Stock Moved<\/strong> has more details.<\/p>\n<p>Amgen\u2019s expansion of some of its drugs, including Prolia, Otezla, Tezspire, and Repatha, is driving its revenue growth, while some of the older drugs, such as Enbrel and Neulasta, are seeing a y-o-y decline in sales. Enbrel \u2013 the rheumatoid arthritis and plaque psoriasis drug, is Amgen\u2019s top-selling product. However, the company has seen the drug\u2019s sales fall to $4.1 billion in 2022, compared to $5.4 billion in 2017. Although Enbrel\u2019s market exclusivity is still far out (2029), it faces increased competition from other companies\u2019 drugs, including AbbVie\u2019s<fbs-ticker data-name=\"ABBV\" data-href=\"https:\/\/www.forbes.com\/companies\/abbvie\" data-type=\"stock\"><br \/>\n  ABBV<br \/>\n <\/fbs-ticker> Rinvoq, Pfizer\u2019s<fbs-ticker data-name=\"PFE\" data-href=\"https:\/\/www.forbes.com\/companies\/pfizer\" data-type=\"stock\"><br \/>\n  PFE<br \/>\n <\/fbs-ticker> Zeljanz, and Johnson &amp; Johnson\u2019s<fbs-ticker data-name=\"JNJ\" data-href=\"https:\/\/www.forbes.com\/companies\/johnson-johnson\" data-type=\"stock\"><br \/>\n  JNJ<br \/>\n <\/fbs-ticker> Stelara. Amgen launched a biosimilar &#8211; Amjevita &#8211; for AbbVie\u2019s Humira. This biosimilar saw a 29% y-o-y growth in sales to $150 million in Q2.<\/p>\n<p><fbs-ad position=\"inread\" progressive=\"\" ad-id=\"article-0-inread\" aria-hidden=\"true\" role=\"presentation\"><\/fbs-ad><\/p>\n<p>Amgen is eyeing inorganic growth to boost its sales and pipeline. Last year, it acquired ChemoCentryx in a $4 billion deal, giving it Tavneos \u2013 a drug approved for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis with potential peak sales of a little over $1 billion. Amgen plans to close its $28 billion Horizon Therapeutics acquisition in December this year. Horizon has two fast-growing drugs, the thyroid eye disease treatment Tepezza and the gout treatment, Krystexxa, with a combined peak sales estimate of over $5 billion. This acquisition will give Amgen ammunition to combat the competition for Enbrel.<\/p>\n<p>The company expects its 2023 sales to be around $27 billion and adjusted earnings to be $18.30 per share at the mid-point of the provided range. With the Horizon acquisition closing toward the end of this year, Amgen will see a jump in 2024 sales, given that Horizon\u2019s last twelve-month sales were $3.6 billion. Looking at valuation, AMGN stock looks fully priced. At its current level of $262, AMGN is trading at 5.2x sales, compared to its last five-year average of 5.1x. Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/AMGN\/no-login-required\/P9VuH452\/Amgen-AMGN-Valuation-Ratios-Comparison?fromforbesandarticle=trefis230814\">Amgen Valuation Ratios Comparison<\/strong> dashboard has more details.<\/p>\n<p>Invest with <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/M7MacZNG?fromforbes\">Market Beating Portfolios<\/strong><\/p>\n<p>See all <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/price-estimates?fromforbes\">Price Estimates<\/strong><\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.forbes.com\/sites\/greatspeculations\/2023\/08\/14\/is-amgen-stock-fully-valued-after-a-17-rise-in-a-month\/\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Amgen stock (NASDAQ NDAQ : AMGN) has seen a 17% rise in a month, outperforming the broader S&amp;P500 index, up 1%. The recent rise can be attributed to its upbeat Q2 results. The company reported revenues of $7.0 billion, up 6% y-o-y, faring better than the consensus estimate of $6.7 billion. Also, its bottom line [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":48285,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[241],"tags":[83],"class_list":["post-48284","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-markets","tag-featured"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Is Amgen Stock Fully Valued After A 17% Rise In A Month? | iFintechWorld<\/title>\n<meta name=\"description\" content=\"Amgen stock (NASDAQ NDAQ : AMGN) has seen a 17% rise in a month, outperforming the broader S&amp;P500 index, up 1%. The recent rise can be attributed to\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=48284\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Is Amgen Stock Fully Valued After A 17% Rise In A Month? | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"Amgen stock (NASDAQ NDAQ : AMGN) has seen a 17% rise in a month, outperforming the broader S&amp;P500 index, up 1%. The recent rise can be attributed to\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=48284\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-14T19:13:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-14T19:13:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/08\/1692040390_0x0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=48284#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=48284\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Is Amgen Stock Fully Valued After A 17% Rise In A Month?\",\"datePublished\":\"2023-08-14T19:13:09+00:00\",\"dateModified\":\"2023-08-14T19:13:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=48284\"},\"wordCount\":573,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Markets\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=48284#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=48284\",\"url\":\"https:\/\/ifintechworld.com\/?p=48284\",\"name\":\"Is Amgen Stock Fully Valued After A 17% Rise In A Month? | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-08-14T19:13:09+00:00\",\"dateModified\":\"2023-08-14T19:13:11+00:00\",\"description\":\"Amgen stock (NASDAQ NDAQ : AMGN) has seen a 17% rise in a month, outperforming the broader S&amp;P500 index, up 1%. The recent rise can be attributed to\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=48284#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=48284\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=48284#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Is Amgen Stock Fully Valued After A 17% Rise In A Month?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Is Amgen Stock Fully Valued After A 17% Rise In A Month? | iFintechWorld","description":"Amgen stock (NASDAQ NDAQ : AMGN) has seen a 17% rise in a month, outperforming the broader S&amp;P500 index, up 1%. The recent rise can be attributed to","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=48284","og_locale":"en_US","og_type":"article","og_title":"Is Amgen Stock Fully Valued After A 17% Rise In A Month? | iFintechWorld","og_description":"Amgen stock (NASDAQ NDAQ : AMGN) has seen a 17% rise in a month, outperforming the broader S&amp;P500 index, up 1%. The recent rise can be attributed to","og_url":"https:\/\/ifintechworld.com\/?p=48284","og_site_name":"iFintechWorld","article_published_time":"2023-08-14T19:13:09+00:00","article_modified_time":"2023-08-14T19:13:11+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/08\/1692040390_0x0.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=48284#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=48284"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Is Amgen Stock Fully Valued After A 17% Rise In A Month?","datePublished":"2023-08-14T19:13:09+00:00","dateModified":"2023-08-14T19:13:11+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=48284"},"wordCount":573,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Markets"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=48284#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=48284","url":"https:\/\/ifintechworld.com\/?p=48284","name":"Is Amgen Stock Fully Valued After A 17% Rise In A Month? | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-08-14T19:13:09+00:00","dateModified":"2023-08-14T19:13:11+00:00","description":"Amgen stock (NASDAQ NDAQ : AMGN) has seen a 17% rise in a month, outperforming the broader S&amp;P500 index, up 1%. The recent rise can be attributed to","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=48284#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=48284"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=48284#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Is Amgen Stock Fully Valued After A 17% Rise In A Month?"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/48284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48284"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/48284\/revisions"}],"predecessor-version":[{"id":48286,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/48284\/revisions\/48286"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/48285"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}